Evaluation of an in-house-developed radioassay kit for antibody detection in cases of pulmonary tuberculosis and tuberculous meningitis

M. Kameswaran, K. Shetty, M. K. Ray, M. A. Jaleel, G. V. Kadival

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A radioassay for the detection of antitubercular antibody has been developed. The technique involves the addition of 125-labeled Mycobacterium tuberculosis antigen as a tracer, diluted clinical sample (serum or cerebrospinal fluid [CSF]), and heat-inactivated Staphylococcus aureus to capture the antibody, incubation for 4 h, and quantitation of the amount of antibody present in the sample. A total of 330 serum samples from patients with pulmonary tuberculosis and 138 control serum samples from individuals who were vaccinated with M. bovis BCG and from patients with pulmonary disorders of nontubercular origin were analyzed. Also, 26 CSF samples from patients with tuberculous meningitis and 24 CSF samples as controls from patients with central nervous system disorders of nontuberculous origin were analyzed. Sensitivities of 80 and 73% were observed for patients with pulmonary tuberculosis and tuberculous meningitis, respectively, and specificities of 90 and 88% were seen for the two groups of patients, respectively. The sensitivity was lower, however, for human immunodeficiency virus-infected patients coinfected with M. tuberculosis. The control population could be differentiated from the patient population. This assay is rapid and user friendly and, with its good sensitivity and specificity, should benefit the population by providing diagnoses early in the course of disease and, hence, permit the early administration of appropriate chemotherapy.

Original languageEnglish (US)
Pages (from-to)987-993
Number of pages7
JournalClinical and Diagnostic Laboratory Immunology
Volume9
Issue number5
DOIs
StatePublished - Sep 2002

Fingerprint

Cerebrospinal fluid
Meningeal Tuberculosis
Pulmonary Tuberculosis
Antibodies
Chemotherapy
Neurology
Cerebrospinal Fluid
Viruses
Assays
Serum
Population
Central Nervous System Diseases
Mycobacterium bovis
Mycobacterium tuberculosis
Staphylococcus aureus
Hot Temperature
HIV
Drug Therapy
Sensitivity and Specificity
Lung

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Evaluation of an in-house-developed radioassay kit for antibody detection in cases of pulmonary tuberculosis and tuberculous meningitis. / Kameswaran, M.; Shetty, K.; Ray, M. K.; Jaleel, M. A.; Kadival, G. V.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 9, No. 5, 09.2002, p. 987-993.

Research output: Contribution to journalArticle

@article{6457c96c88c2462894d3a3ce5d1022e8,
title = "Evaluation of an in-house-developed radioassay kit for antibody detection in cases of pulmonary tuberculosis and tuberculous meningitis",
abstract = "A radioassay for the detection of antitubercular antibody has been developed. The technique involves the addition of 125-labeled Mycobacterium tuberculosis antigen as a tracer, diluted clinical sample (serum or cerebrospinal fluid [CSF]), and heat-inactivated Staphylococcus aureus to capture the antibody, incubation for 4 h, and quantitation of the amount of antibody present in the sample. A total of 330 serum samples from patients with pulmonary tuberculosis and 138 control serum samples from individuals who were vaccinated with M. bovis BCG and from patients with pulmonary disorders of nontubercular origin were analyzed. Also, 26 CSF samples from patients with tuberculous meningitis and 24 CSF samples as controls from patients with central nervous system disorders of nontuberculous origin were analyzed. Sensitivities of 80 and 73{\%} were observed for patients with pulmonary tuberculosis and tuberculous meningitis, respectively, and specificities of 90 and 88{\%} were seen for the two groups of patients, respectively. The sensitivity was lower, however, for human immunodeficiency virus-infected patients coinfected with M. tuberculosis. The control population could be differentiated from the patient population. This assay is rapid and user friendly and, with its good sensitivity and specificity, should benefit the population by providing diagnoses early in the course of disease and, hence, permit the early administration of appropriate chemotherapy.",
author = "M. Kameswaran and K. Shetty and Ray, {M. K.} and Jaleel, {M. A.} and Kadival, {G. V.}",
year = "2002",
month = "9",
doi = "10.1128/CDLI.9.5.987-993.2002",
language = "English (US)",
volume = "9",
pages = "987--993",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Evaluation of an in-house-developed radioassay kit for antibody detection in cases of pulmonary tuberculosis and tuberculous meningitis

AU - Kameswaran, M.

AU - Shetty, K.

AU - Ray, M. K.

AU - Jaleel, M. A.

AU - Kadival, G. V.

PY - 2002/9

Y1 - 2002/9

N2 - A radioassay for the detection of antitubercular antibody has been developed. The technique involves the addition of 125-labeled Mycobacterium tuberculosis antigen as a tracer, diluted clinical sample (serum or cerebrospinal fluid [CSF]), and heat-inactivated Staphylococcus aureus to capture the antibody, incubation for 4 h, and quantitation of the amount of antibody present in the sample. A total of 330 serum samples from patients with pulmonary tuberculosis and 138 control serum samples from individuals who were vaccinated with M. bovis BCG and from patients with pulmonary disorders of nontubercular origin were analyzed. Also, 26 CSF samples from patients with tuberculous meningitis and 24 CSF samples as controls from patients with central nervous system disorders of nontuberculous origin were analyzed. Sensitivities of 80 and 73% were observed for patients with pulmonary tuberculosis and tuberculous meningitis, respectively, and specificities of 90 and 88% were seen for the two groups of patients, respectively. The sensitivity was lower, however, for human immunodeficiency virus-infected patients coinfected with M. tuberculosis. The control population could be differentiated from the patient population. This assay is rapid and user friendly and, with its good sensitivity and specificity, should benefit the population by providing diagnoses early in the course of disease and, hence, permit the early administration of appropriate chemotherapy.

AB - A radioassay for the detection of antitubercular antibody has been developed. The technique involves the addition of 125-labeled Mycobacterium tuberculosis antigen as a tracer, diluted clinical sample (serum or cerebrospinal fluid [CSF]), and heat-inactivated Staphylococcus aureus to capture the antibody, incubation for 4 h, and quantitation of the amount of antibody present in the sample. A total of 330 serum samples from patients with pulmonary tuberculosis and 138 control serum samples from individuals who were vaccinated with M. bovis BCG and from patients with pulmonary disorders of nontubercular origin were analyzed. Also, 26 CSF samples from patients with tuberculous meningitis and 24 CSF samples as controls from patients with central nervous system disorders of nontuberculous origin were analyzed. Sensitivities of 80 and 73% were observed for patients with pulmonary tuberculosis and tuberculous meningitis, respectively, and specificities of 90 and 88% were seen for the two groups of patients, respectively. The sensitivity was lower, however, for human immunodeficiency virus-infected patients coinfected with M. tuberculosis. The control population could be differentiated from the patient population. This assay is rapid and user friendly and, with its good sensitivity and specificity, should benefit the population by providing diagnoses early in the course of disease and, hence, permit the early administration of appropriate chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036731922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036731922&partnerID=8YFLogxK

U2 - 10.1128/CDLI.9.5.987-993.2002

DO - 10.1128/CDLI.9.5.987-993.2002

M3 - Article

VL - 9

SP - 987

EP - 993

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 5

ER -